Statement of Changes in Beneficial Ownership (4)
December 10 2021 - 11:28AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
KELLY JUSTYNA |
2. Issuer Name and Ticker or Trading Symbol
POINT Biopharma Global Inc.
[
PNT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer |
(Last)
(First)
(Middle)
4850 WEST 78TH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/9/2021 |
(Street)
INDIANAPOLIS, IN 46268
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $6.40 | 12/9/2021 | | A | | 70000 | | (1) | 12/9/2027 | Common Stock | 70000 | $0.00 | 70000 | D | |
Explanation of Responses: |
(1) | The option vests 25% on December 9, 2022 with the remaining 75% vesting in three equal annual installments thereafter. Notwithstanding the foregoing, upon any Sale Event (as defined in the Issuer's 2021 Plan), any outstanding stock options shall automatically become fully vested and exercisable as of the effective time of the Sale Event. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
KELLY JUSTYNA 4850 WEST 78TH STREET INDIANAPOLIS, IN 46268 |
|
| Chief Operating Officer |
|
Signatures
|
/s/ William L. Demers, by Power of Attorney for Justyna Kelly | | 12/10/2021 |
**Signature of Reporting Person | Date |
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Jul 2023 to Jul 2024